Although many compounds are generated during the drug discovery process, only a handful can actually reach becoming the final medicinal product, and most such compounds end up disappearing without coming into the spotlight. However, it is highly possible that some of these compounds may retain very significant potential. The acronym GEXVal was devised as a shortened form of Generate Extra Value, which refers to the process of identifying such promising compounds and nurturing new value through repositioning research.